Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naïve ferrets (Q30398626)

21 June 2017

title

Pandemic H1N1 vaccine requires the use of an adjuvant to protect against challenge in naïve ferrets (English)

1 reference

21 June 2017

0 references

12

Albert D M E Osterhaus

1 reference

21 June 2017

8

Geert van Amerongen

1 reference

21 June 2017

3

Koert J Stittelaar

1 reference

21 June 2017

Judith M A van den Brand

7

object named as

Judith M A van den Brand

1 reference

21 June 2017

Benoît Baras

1

1 reference

21 June 2017

Leon de Waal

2

1 reference

21 June 2017

Valérie Jacob

4

1 reference

21 June 2017

Sandra Giannini

5

1 reference

21 June 2017

Edwin J B Veldhuis Kroeze

6

1 reference

21 June 2017

James H Simon

9

1 reference

21 June 2017

Emmanuel Hanon

10

1 reference

21 June 2017

Sally P Mossman

11

1 reference

21 June 2017

language of work or name

English

0 references

publication date

14 January 2011

1 reference

21 June 2017

1 reference

21 June 2017

volume

29

1 reference

21 June 2017

issue

11

1 reference

21 June 2017

page(s)

2120-2126

1 reference

Pandemic potential of a strain of influenza A (H1N1): early findings

21 June 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.125

Cross-reactive antibody responses to the 2009 pandemic H1N1 influenza virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.125

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.125

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.125

Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.125

Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.125

Ferrets and the challenges of H5N1 vaccine formulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.125

Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.125

Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.125

Severity of pneumonia due to new H1N1 influenza virus in ferrets is intermediate between that due to seasonal H1N1 virus and highly pathogenic avian influenza H5N1 virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.125

Seasonal influenza vaccine provides priming for A/H1N1 immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.125

Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.125

Infection of mice with a human influenza A/H3N2 virus induces protective immunity against lethal infection with influenza A/H5N1 virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.125

Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.125

T cell responses are better correlates of vaccine protection in the elderly

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.125

Targeting the innate immune response with improved vaccine adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.125

Cellular immunity induced by the recombinant Plasmodium falciparum malaria vaccine, RTS,S/AS02, in semi-immune adults in The Gambia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.125

A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.125

Potent enhancement of cellular and humoral immune responses against recombinant hepatitis B antigens using AS02A adjuvant in healthy adults

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.125

Assessment of seasonal influenza A virus-specific CD4 T-cell responses to 2009 pandemic H1N1 swine-origin influenza A virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.125

Current status and progress of prepandemic and pandemic influenza vaccine development.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.125

Response to a monovalent 2009 influenza A (H1N1) vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.125

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.125

A novel influenza A (H1N1) vaccine in various age groups.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.125

Responses to 2009 H1N1 vaccine in children 3 to 17 years of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.125

Longevity of the protective immune response induced after vaccination with one or two doses of AS03A-adjuvanted split H5N1 vaccine in ferrets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.125

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.125

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.12.125

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2010.12.125

1 reference

21 June 2017

1 reference